 pDJA1, a cardiac specific gene, corresponding proteins, and uses thereof |
| OF THE INVENTION Before the present methods and treatment methodology are described, it is to be ... |
|
| GPIb.alpha. fragments and recombinant DNA expression vectors |
| As set forth in aforementioned application Ser. No. 07/470,674, there are provided peptides ... |
|
| Expression vector encoding hybrid immunoglobulins |
| Ligand binding partners as defined herein are proteins known to function to bind specifically to ... |
|
| Hybrid immunoglobulins |
| Ligand binding partners as defined herein are proteins known to function to bind specifically to ... |
|
| GPIb-lipid complex and uses thereof |
| What is claimed is: 1. A complex comprising a lipid and a conjugate of GPIb or a GPIB fragment ... |
|
| Immuno-modulating antitumor activities of Ganoderma lucidum (Reishi) polysaccharides |
| We claim: 1. A composition comprising one or more fractions, the one or more fractions obtainable ... |
|
| Painless electrolyte solutions |
| What is claimed is: 1. A composition consisting of: (a) electrolytes selected from the group ... |
|
| Method for enhancing healing of corneal endothelial wounds |
| Method using a non-steroidal antiinflammatory compound, such as indomethacin, and/or a growth ... |
|
| Method and agents for promoting wound healing |
| In accordance with the present invention, diagnostic and therapeutic protocols are proposed that ... |
|
|
.alpha.-.beta. C4BP-type recombinant heteromultimeric proteins
| Details |
Inventors: Klatzmann, David; Cohen, Jacques;
Assignee: Universite Pierre et Marie Curie (Paris VI) (Paris, FR) Universite de Reims Champagne-Ardennes (Reims, FR)
Primary Examiner: Mertz; Prema
Assistant Examiner:
Attorney, Agent or Firm: Venable LLP Gollin; Michael A. Axelrod; Nancy J.
A recombinant heteromultimeric protein including at least (a) a polypeptide fusion molecule A consisting of a C4BP .alpha.-chain C-terminal fragment and a polypeptide fragment heterologous to said .alpha.-chain, and (a) a polypeptide fusion molecule B consisting of a C4BP .beta.-chain C-terminal fragment and a polypeptide fragment heterologous to said .beta.-chain, wherein (a) and (b) are linked in the C-terminal portion to form said multimeric protein. |
|
DETAILED DESCRIPTION The object of the present invention is therefore to develop recombinant soluble heteromultimeric chimeric molecules which combine different functions in one and the same molecule, with a view to achieving immunointervention in human immune pathologies.
These molecules will make it possible to intervene in the physiopathological mechanisms of different ailments, in particular in the spheres relating to: the pathology of the transport and elimination of immune complexes by the erythrocytes, with an application, in particular, to disseminated lupus erythematosus, or to HIV infections, the capture of antigens which is mediated by Fc receptors on the surface of the cells of the monocyte/macrophage cell line, modulation by molecules having soluble CD16 activity, the prevention of anti-erythrocyte Rh(D) alloimmunization, the inhibition of cell penetration by the HIV virus using soluble forms of CD4, antibodies which are directed against the constituents of the virus, and/or molecules having enzymic functions.
The present invention relates to a recombinant multimeric protein which is characterized in that it comprises at least: a) a polypeptide fusion molecule A, which consists of a C-terminal fragment of the .
alpha.
chain of C4BP, contained between amino acids 549 and 124, and a polypeptide fragment which is heterologous in relation to said .
alpha.
chain, b) a polypeptide fusion molecule B, which consists of a C-terminal fragment of the .
beta.
chain of C4BP, contained between amino acids 235 and 120, and a polypeptide fragment which is heterologous in relation to the .
beta.
chain, with amino acids 549 or 235 representing the respective C-terminal ends of the fusion molecules and the heterologous fragments being fused by their C-terminal end to the residue of the .
alpha.
and .
beta.
chains, respectively, and with the molecules in a) and b) being linked to each other by way of their C-terminal moiety in order to form said multimeric protein.
Preferably, a recombinant multimeric protein according to the invention is characterized in that the C-terminal fragment of the
|
| Related patents |
|
|
Semi-refined carrageenan
The present invention provides methods for preparing a carrageenan product comprising the steps of providing a carrageenan-containing seaweed material having a seaweed ...
|
|
|
Method for improving genetic stability of foreign insert nucleotide sequence in recombinant poliovirus
To be free from shortcomings of the poliovirus vector systems, in particular, genetic instability of the foreign insert integrated into the recombinant polioviruses, the ...
|
|
|
Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
The invention relates to adult dedifferentiated programmable stem cells derived from human monocytes, as well as their production and use for the production of body ...
|
|
|
Peptides which enhance transport across tissues and methods of identifying and using the same
The invention provides a method of identifying a peptide which permits or facilitates the transport of an active agent through a human or animal tissue. A predetermined ...
|
|
|
Synthetic peptides and kits for diagnosis of anti-phospholipid syndrome
The invention claimed is: 1. A synthetic peptide selected from the group consisting: (i) a peptide of SEQ ID NO:1 to SEQ ID NO: 7, of the sequences: Leu-Lys-Thr-Pro-Arg-V...
|
|
|
Synthetic peptide inhibitors of HIV transmission
OF THE INVENTION 5.1 DP-178 AND DP-178-LIKE PEPTIDES 5.2 ASSAYS FOR ANTIVIRAL ACTIVITY 5.3 USES OF THE PEPTIDES OF THE INVENTION 6. EXAMPLE: DP-178 (SEQ ID:1) IS A POTEN...
|
|
|
Compounds which inhibit HIV replication
A first aspect of the present invention is a peptide selected from the group consisting of: (a) the peptide DP-107, which has the formula, from amino terminus to carboxy ...
|
|
|
Hybrid polypeptides with enhanced pharmacokinetic properties
OF THE INVENTION Described herein are peptide sequences, referred to as enhancer peptide sequences, derived from various retroviral envelope (gp41) protein sequences ...
|
|
|
1-aryl-2-hydroxyethyl amides as potassium channel openers
OF THE INVENTION The present invention provides novel aryl hydroxyethyl amides and related derivatives which are modulators of the KCNQ potassium channels and which ...
|
|
|
Method of eliciting anti-HIV-1 helper T cell responses
A number of HIV-1 p24 peptides that elicit HIV-1-specific helper T cell responses have been identified. Contemplated within the scope of this invention are methods of ...
|
|
|
Drugs 
